Inability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)
The patient will receive thoracic stereotactic body radiotherapy at MD Anderson.
Pathology review at MD Anderson Cancer Center. The volume of disease must be high enough for the surgeon to agree to include an extended template pelvic lymph node dissection
Pathology review at Monroe Dunaway (MD) Anderson (Note: if patientâ€™s prostate biopsy was not read at MD Anderson, it must be reviewed at the study site to confirm eligibility).
Consent to MD Anderson companion laboratory protocol 2014-0938.
Estimated time to first treatment of 3 years or less according to MD Anderson Cancer Center (MDACC) nomogram.
Consent to MD Anderson laboratory protocol PA13-0291 and LAB02-152.
Consent to MD Anderson laboratory protocol PA13-0291.
Histological documentation of adenocarcinoma of the prostate reviewed at MD Anderson Cancer Center. Patients with small cell, neuroendocrine, or transitional cell carcinomas are not eligible.
Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption
Patient who are capable to return to MD Anderson Cancer Center (MDACC) for follow-up
Patients must have tissue resected by transurethral resection of bladder tissue (TURBT) at the MD Anderson Cancer Center
Patients willing to be treated with frame-based gamma knife SRS at MD Anderson main campus or MD Anderson at the Woodlands
Patients must agree to tissue collection for correlative studies (including participation in PA13-0291 and PA13-0247 for MD Anderson participants) at the specified timepoints
Patients must have a lesion amenable to resection for the generation of TIL on MD Anderson protocol 2004-0069
Patients must have adequate TIL that were previously harvested and then cryopreserved on MD Anderson Cancer Center (MDACC) protocol 2004-0069
Histologically confirmed diagnosis of adenocarcinoma of the prostate within one year of study entry; evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD Anderson
Patients must not be considered a candidate for a complete surgical cytoreductive surgery; this determination will be made through either discussion at MD Anderson peritoneal surface malignancy multidisciplinary review or consultation with MD Anderson peritoneal surgeon
Patients must be willing to stay within 2 hours drive of MD Anderson Cancer Center whilst receiving Ipilimumab therapy. Patient must also agree to present to MD Anderson emergency center while on Ipilimumab therapy.
Newly diagnosed patients with stage I and II follicular lymphoma, pathologically confirmed at MD Anderson Cancer Center (MDACC) to be grade 1 or 2
Patients may be on other trials (either here at M.D. Anderson Cancer Center or at an outside institution) as long as the other eligibility criteria are met
RENAL & BLADDER COHORT: Consent to Monroe Dunaway (MD) Anderson laboratory protocol PA13-0291
BLADDER: Patients must be considered to be an operative candidate by the urology service at MD Anderson Cancer Center
Histopathologic documentation (must be performed or reviewed at MD Anderson) of recurrent high grade epithelial ovarian cancer.
FOR PDX-GUIDED THERAPY THROUGH ONGOING TRIALS AT MD ANDERSON OR OFF-PROTOCOL WITH STANDARD OF CARE (PART 2): The patient PDXs must have generated informative mouse xenograft data during Part 1 to participate in Part 2.
FOR PDX-GUIDED THERAPY THROUGH ONGOING TRIALS AT MD ANDERSON OR OFF-PROTOCOL WITH STANDARD OF CARE (PART 2): Patients should ideally have bi-dimensional measurable disease (leukemia phase only, bone marrow only, splenomegaly only, or GI involvement only is acceptable).
FOR PDX-GUIDED THERAPY THROUGH ONGOING TRIALS AT MD ANDERSON OR OFF-PROTOCOL WITH STANDARD OF CARE (PART 2): Patients must have adequate organ function for drugs(s) or combination being utilized (dependent on the drug (s) being given).
Patients must have consented to the MD Anderson ATTACC protocol prior to inclusion
Bone only disease if there are lytic lesions is also allowed and treatment response will be evaluated based on the MD Anderson criteria
Eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician
Patient plans to receive treatment at MD Anderson
Patients with a pathologically proven diagnosis of NSCLC and consented to receive CXRT at MD Anderson
Intention for chemotherapy administration at MD Anderson Cancer Center
Consent to MD Anderson laboratory protocol PA13-0291
Histological documentation of adenocarcinoma of the prostate reviewed at MD Anderson Cancer Center; patients with small cell, neuroendocrine, or transitional cell carcinomas are not eligible
Unwilling to participate in follow-up clinical appointments at MD Anderson Cancer Center (MDACC)
Serum bilirubin < 1.5 x upper limit of normal (ULN) (maximum level based on MD Anderson laboratory ranges is 1.95 mg/dL)
Radiation treatment for this cancer was completed (or will be completed) at MD Anderson Cancer Center (post-RT study only)
Seen at an outpatient clinic at MD Anderson Cancer Center or The Harris Health System (LBJ) Hospital General Oncology Clinic.
Patients undergoing open liver resection without bowel resection/anastomosis for malignancy at MD Anderson Cancer Center
All patients undergoing RC for bladder cancer with urinary diversion at MD Anderson Cancer Center (MDACC).
Is scheduled to undergo cystoscopy with bladder resection procedure under general anesthesia requiring neuromuscular relaxation using rocuronium bromide to secure airway and requiring neuromuscular reversal at The University of Texas Monroe Dunaway (MD) Anderson Cancer Center - Mays Clinic (ambulatory care building [ACB]-outpatient)
Outpatient at MD Anderson Cancer Center
Patients seen by palliative care, thoracic oncology, pulmonary medicine, or emergency care at MD Anderson Cancer Center
Patients who are receiving neoadjuvant chemotherapy treatment at University of Texas (UT) MD Anderson Cancer Center
Patients who are not receiving their primary cancer care and chemotherapy at MD Anderson Cancer Center
Have been scheduled for an intramedullary nailing (IM) surgery with the department of Orthopaedic Oncology at University of Texas (UT) MD Anderson Cancer Center
History of curative-intent radiotherapy at MD Anderson Cancer Center (MDACC) for a new primary H&N cancer in past 15 years
PATIENTS ONLY: Currently receiving treatment (e.g. radiotherapy, chemotherapy) at MD Anderson Cancer Center
Must be willing to come to MD Anderson Main Campus (Texas Medical Center) for intervention
Outpatient at MD Anderson Cancer Center seen by the supportive care service, thoracic medical oncology, cancer pain clinic, or cardiopulmonary clinic
Willing to come to MD Anderson for the intake and follow up data acquisition and to receive their equipment.
Willing to allow research staff to come to their homes or to return the equipment to MD Anderson (MDA) in the case of equipment malfunction.
Patients at MD Anderson with a cancer history who are either undergoing active treatment or who have completed treatment for their cancer
Willing to come to MD Anderson Main Campus (Texas Medical Center) for enrollment
To preserve a homogenous cohort and comply with the departmentally-organized research infrastructure, we will include preoperative abdominal cancer patients undergoing surgery, or healthcare provider from all specialties at MD Anderson Cancer Center (MDACC) or volunteer from MDACC Volunteer Service.
Inpatient at MD Anderson seen by palliative care team
Willing to come to MD Anderson Cancer Center (MDACC) or Hospital Israelita Albert Einstein (HIAE) for the meditation sessions and assessment sessions
Patients with a pathologically proven diagnosis of CRC seen either at MD Anderson or Lyndon B Johnson General Hospital (LBJ)
Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service, Thoracic Medical Oncology or Cardiopulmonary Center
Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service or Thoracic Medical Oncology
Patients with normal renal function according to MD Anderson testing standards and no prior renal disease
Patients with normal hepatic function according to MD Anderson testing standards and no prior liver disease
Minocycline trial only: patients with adequate renal function according to MD Anderson testing standards (screening cut off for serum creatinine < 2 times the upper limit of normal)
Minocycline trial only: patients with adequate hepatic function according to MD Anderson testing standards
Outpatients at Monroe Dunaway (MD) Anderson Cancer Center seen by the Supportive Care, Rehabilitation Service, Thoracic Oncology or Pulmonary Medicine
Inability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)
Patients undergoing liver and/or pancreatic surgical resection for malignancy at MD Anderson Cancer Center
Patients who intend to remain under the MD Anderson Cancer Center (MDACC) surgeon's care until completion of the reconstruction
All patients with mesothelioma or other pathologies undergoing a pleurectomy decortication at MD Anderson Cancer Center
MD Anderson patient
Not engaged in smoking cessation treatment other than the MD Anderson Cancer Center (MDACC) Tobacco Treatment Program
Cases without prior biopsy will be chosen based upon consensus of a MD Anderson faculty neuroradiologist and neurosurgeon for high probability of representing a glioblastoma
Newly diagnosed biopsy proven locoregional invasive breast cancer at MD Anderson Cancer Center, or referred to MD Anderson for treatment after initial radiologic (mammographic, sonographic, etc.) exams at an outside institution in whom NAC is planned
Women undergoing cold knife cone (CKC) of the cervix at MD Anderson
Enrolled at MD Anderson Cancer Center (MDACC), written consent
GROUP 2: Oncologic patients at MD Anderson Cancer Center (MDACC):
Persons presenting for: physical or dental exams at outside health care centers OR research meetings/gatherings OR subjects identified at MD Anderson Cancer Center (MDACC) who are not already diagnosed with oral cancer or pre oral cancer: this includes patients with malignancies other than oral cancer, and visitors and family members, attendees of the National Health Service (HNS) Oral Cancer Screening event who are willing to participate
Participants must have been clinically diagnosed with breast cancer and scheduled for axillary lymph node dissection (ALND) and radiation treatment at MD Anderson (receiving chemotherapy, mastectomy or breast-conserving surgery, ALND (>10 nodes) and radiation treatment for breast cancer, identified by Drs. Mittendorf and Shaitelman of the Nellie B. Connally Breast Cancer Center at MD Anderson)
For clinical provider participants: Clinical provider at a Houston Area Location of MD Anderson assigned to the intervention
Admitted to being a current smoker or recent quitter upon admission to MD Anderson Cancer Center (MDACC) (Arm 4)
